Company · TENX
Tenax Therapeutics, Inc.
Name as listed on its exchange; filed with the SEC as TENAX THERAPEUTICS, INC.
Nasdaq's symbol directory lists TENX on Nasdaq as “Tenax Therapeutics, Inc. - Common Stock”.
In the 12 months to Nov 8, 2026: insiders bought on 13 occasions ($4.8M); 18 filings by holders of 5% or more; 3 company reports (Form 8-K, since May 26, 2026).
Insider trades · SEC Form 4
Those inside the hall
Open-market purchases and sales only. Legs one person filed for one day are combined.
Who traded
- ADAR1 Capital Management, LLC bought $4.7M
- Doogan Declan bought $102K
- Giordano Christopher Thomas, CEO bought $20K
- STAAB THOMAS R II, Chief Financial Officer bought $11K
Every trade (13)
- BUYADAR1 Capital Management, LLC bought $551K
- BUYADAR1 Capital Management, LLC bought $406K
- BUYADAR1 Capital Management, LLC bought $507K
- BUYDoogan Declan bought $102K
- BUYGiordano Christopher Thomas, CEO bought $9K
- BUYGiordano Christopher Thomas, CEO bought $11K
- BUYSTAAB THOMAS R II, Chief Financial Officer bought $11K
- BUYADAR1 Capital Management, LLC bought $338K
- BUYADAR1 Capital Management, LLC bought $322K
- BUYADAR1 Capital Management, LLC bought $723K
- BUYADAR1 Capital Management, LLC bought $188K
- BUYADAR1 Capital Management, LLC bought $1.3M
- BUYADAR1 Capital Management, LLC bought $360K
Large holders · SEC Schedules 13D and 13G
Five percent and over
Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G
- BlackRock, Inc. 7.5%
- Millennium Management LLC 3.6%
- Sphera Funds Management Ltd. 7.09%
- Dellora Investments Master Fund LP 6.4%
- ING Groep N.V. 0%
- ADAR1 Capital Management, LLC 14%
- FMR LLC 1.4%
- ING GROEP NV 7.05%
- SPHERA FUNDS MANAGEMENT LTD. 5.33%
- MILLENNIUM MANAGEMENT LLC 5.8%
- BIOTECHNOLOGY VALUE FUND L P 9.99%
- RTW Investments, LP 9.9%
- Vivo Opportunity Fund Holdings, L.P. 9%
- Venrock Healthcare Capital Partners III, L.P. 4.7%
- Perceptive Advisors LLC 4.5%
- Ikarian Capital, LLC 2.9%
- Adage Capital Management, L.P. 6.81%
- Giordano Christopher Thomas 4.32%
Company reports · SEC Form 8-K
In its own words
Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.
- Results of operations and financial condition Nov 5, 2026
- Other events Oct 8, 2026
- Regulation FD disclosure Sep 9, 2026
Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.